While millions of HIV-infected patients in sub-Saharan Africa are now receiving life-saving antiretroviral therapy, early mortality is much higher than expected, and the extent of CD4+ T cell recovery is highly variable. Understanding the predictors of CD4+ T cell recovery will be important to optimize the effectiveness of antiretroviral treatment programs in sub-Saharan Africa. We hypothesize that persistent generalized T cell activation is an important determinant of blunted CD4+ T cell recovery in sub-Saharan Africans. While T cell activation declines significantly during suppressive antiretroviral therapy, it remains abnormally elevated and has been associated with blunted CD4+ T cell recovery in resource-rich settings. While the determinants of T cell activation remain unknown, stimulation of innate immune responses by residual HIV replication and by other co- infections are likely mechanisms. HIV and co-infections may stimulate innate immune responses by activating natural killer (NK) cells through killer immunoglobulin-like receptor (KIR) - human leukocyte antigen (HLA) interactions and by binding toll-like receptors (TLR). Several KIR/HLA allotypes and TLR polymorphisms have been associated with activation or inhibition of innate immune responses to HIV and prevalent co-infections and with clinical progression during untreated HIV-1 infection. Whether these host genetic factors are associated with T cell activation and CD4+ T cell recovery during suppressive antiretroviral therapy remains unknown. We propose to assess whether KIR/HLA allotypes and TLR polymorphisms are associated with persistent T cell activation (% CD38+ HLA-DR+ CD8+ T cells) and the rate of CD4+ T cell recovery in 400 HIV-infected Ugandans maintaining viral suppression on their first antiretroviral treatment regimen and followed every 3 months for a median of 24 months. We will perform these studies using samples from the well- characterized UARTO cohort in Mbarara, Uganda (a representative cohort of HIV- infected Ugandans intiating antiretroviral therapy) and in collaboration with the Carrington lab at NCI-Frederick;the UCSF Genomics Core Facility;and the Cao Laboratory in Kampala, Uganda. This work will help identify inflammatory pathways influencing treatment-mediated CD4+ T cell recovery, identifying targets for interventions to optimize the effectiveness of antiretroviral therapy in sub-Saharan Africa.

Public Health Relevance

While millions of HIV-infected patients in sub-Saharan Africa are finally receiving life- saving HIV medications, death rates remain high, and many fail to regain normal immune function. Excessive stimulation of the innate immune system by residual HIV replication and other prevalent infections like tuberculosis and malaria may prevent full recovery of the immune system in these patients. This research project will help identify inflammatory pathways that prevent immune system recovery in these patients, eventually leading to targeted interventions to improve immune system recovery.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI078774-02
Application #
7847584
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Livnat, Daniella
Project Start
2009-05-22
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
2
Fiscal Year
2010
Total Cost
$187,901
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Siedner, Mark J; Kim, June-Ho; Nakku, Ruth Sentongo et al. (2016) HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. AIDS 30:667-70
Okello, Samson; Asiimwe, Stephen B; Kanyesigye, Michael et al. (2016) D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. J Acquir Immune Defic Syndr 73:396-402
Siedner, Mark J; Kim, June-Ho; Nakku, Ruth Sentongo et al. (2016) Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy. J Infect Dis 213:370-8
Lee, Sulggi A; Mefford, Joel A; Huang, Yong et al. (2016) Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS 30:1807-15
Byakwaga, Helen; Hunt, Peter W; Laker-Oketta, Miriam et al. (2015) The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa. J Acquir Immune Defic Syndr 70:296-303
Byakwaga, Helen; Boum 2nd, Yap; Huang, Yong et al. (2014) The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis 210:383-91
Martinez, Priscilla; Tsai, Alexander C; Muzoora, Conrad et al. (2014) Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. J Acquir Immune Defic Syndr 65:456-62
Lee, Sulggi A; Sinclair, Elizabeth; Hatano, Hiroyu et al. (2014) Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One 9:e89444
Serrano-Villar, Sergio; Sainz, Talia; Lee, Sulggi A et al. (2014) HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 10:e1004078
Huang, Yong; Louie, Alexander; Yang, Qiyun et al. (2013) A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients. Bioanalysis 5:1397-407

Showing the most recent 10 out of 12 publications